

CURRICULUM VITAE

2020-02-14

Kristian Bolin

Professor of Health Economics, Department of Economics, University of Gothenburg

Director Centre for Health Economics, University of Gothenburg

Ph.D. Economics (filosofie doktor, nationalekonomi, 1996)

Associate Professor (Docent) Department of Economics, Lund University (2002)

Full Professor of Economics, Lund University (2009)

Professor of Health Economics, University of Gothenburg, 2013-08-01 -

Scientific qualifications

Participates(-ed) in the following research projects

- (1) Project *The economics of the old baby-boomers: Withdrawal from the labour market, housing, wealth accumulation, health and the demand for health care and old age care* (funded by FAS, directed by prof. Anders Klevmarcken); years 2001 – 2005.
- (2) Project *Kostnadseffektiv insamling och bearbetning av belastningsdata i arbetslivet – strategier för praktiker* (cost-effective collection and processing of work-related exposure data; funded by the Swedish Council for Working Life and Social Research (FAS), directed by prof. Svend Erik Mathiassen).
- (3) Programme *Health, Labour Force Participation, and Living Conditions in an Ageing Europe – A Comparative Policy analysis* (funded by FAS, directed by prof. Björn Lindgren);
- (4) Project *Hälsa och livsstil i det hälsoekonomiska perspektivet – Betydelsen av familjestruktur, hälsopolitiska åtgärder, sociala trygghetssystem och individuella försäkringar för unga människors livsstil och framtida hälsa* (Funded by Länsförsäkringars forskningsstiftelse, directed by prof. Björn Lindgren); years 2004 – 2005.
- (5) Project *Hälsa, Sociala trygghetssystem och individuella försäkringar – En hälsoekonomisk analys av samspelet mellan alternativa försäkringslösningar och hälsan i tolv länder i Europa* (Health, Social and individual insurance – a health economic analysis of the interaction between the organisation of insurance and health in Europa; funded by Trygg-Hansas forskningsstiftelse, directed by prof. Björn Lindgren); years 2004 – 2005.
- (6) Programme *Centre for Economic Demography (CED) at Lund University*. Participant of the application for long-term funding (“Linnéstöd”) from the Swedish Research Council for establishing the Centre for Economic Demography at Lund University. The program was granted funding in 2006. The program is ongoing. (More information at <http://www.ed.lu.se/EN/>)

Leader of the following research projects

- (7) Project *Livsstil, sjukdom och läkemedelsanvändning – hälsoekonomiska analyser av betydelsen av livsstilsval för sjukdom och läkemedelsanvändning*. (Lifestyle, sickness and the utilisation of pharmaceuticals – health economic analyses of the importance of lifestyle for sickness and the utilisation of pharmaceuticals; funded by Stiftelsen Apoteket AB:s fond för forskning och studier i hälsoekonomi och samhällsfarmaci).
- (8) Country team leader (2006 – 2008), Sweden, in the joint European project SHARE (Survey of Health and Retirement in Europe), with the purpose of creating a multinational paneldata base. The SHARE data collection has been primarily funded by the European Commission through the 5th framework programme (project QLK6-CT-2001-00360 in the thematic programme Quality of Life). Additional funding came from the US National Institute on Ageing and, for the Swedish participation, from Bank of Sweden Tercentenary Foundation (Riksbankens Jubileumsfond), Swedish Council for working Life and Social Research (FAS), and the Swedish Social Insurance Agency (Försäkringskassan). (More information at <http://www.share-project.org/>)

- (9) Project *De cancersjukas livssituation i ett hälsoekonomiskt perspektiv – Betydelsen av cancersjukdom under barn- och ungdomsåren respektive i vuxen ålder för individens utbildning, arbetsmarknadsaktiviteter, familjebildning och hälsa* (a health economic perspective on the life situation of cancer patients – the importance of cancer for education, labour market activities, family formation and health; funded by Cancerfonden).
- (10) Head of the research-platform *Persons with long-term illness and functional disabilities* (2007 – 2009; 50 % of full time; The Vårdal Institute). The Vårdal Institute is a national environment for research and development in the field of health care and social service in close cooperation with the universities and the health care principals. (More information: www.vardalinstitutet.net)
- (11) BIOlogical therapy CYCLEs towards tailored, needs-driven, safer and cost-effective management of Crohn's disease (BIOCYCLE). The Centre for Health Economics at Gothenburg University (CHEGU) is responsible for the health economics part of the project. The project is funded within the Horizon 2020 - Research and Innovation Framework Programme.
- (12) A new unique diagnostic test for rheumatoid arthritis. The Centre for Health Economics at Gothenburg University (CHEGU) is responsible for the health economics part of the project is funded by the Swedish Research Council.

Other scientific/ consultancy assignments (a selection)

Member of the graduation committee for PhD defence (>10)
 Scientific advisor to The National Institute of Public Health;
 Scientific advisor to the National Board of Health and Welfare (as health economics advisor in the development of clinical national guidelines);
 Participated in the SOU (statens offentliga utredningar). *Familj, makt och ekonomiska resurser – den nya familjeekonomin*. SOU 1997:138;
 Scientific advisor to Ministry of Health and Social Affairs. *The Simulating An Ageing Population. A Micro-simulation Approach Applied to Sweden*.
 Scientific advisor to Ministry of Health and Social Affairs (the project *LEV– utveckling av sjukvårdsmodellen i SESIM*);
 Scientific advisor to the following pharmaceutical companies: Astra Zeneca, GlaxoSmithKline, Pfizer, UCB Nordic, and MSD;
 Scientific advisor to LIF - the organization for the research-based pharmaceutical industry in Sweden.
 Consultant for Vårdanalys.
 Consultant for The Dental and Pharmaceutical Benefits Agency (TLV)

Editor

Michael Grossman (City University of New York) and Björn Lindgren (Lund University) have been series co-editors for *Advances in Health Economics and Health Services Research* since 2005. In 2010, Bob Kaestner (University of Illinois at Chicago) and Kristian Bolin (Lund University) joined Björn and Michael as series co-editors for future volumes.

Supervision

I have been the main supervisor of six doctoral students, five at Lund University and one at the University of Gothenburg: (1) Henrik Andersson who defended his thesis in 2005 (title: *Willingness to Pay for a Reduction in Road Mortality Risk: Evidence from Sweden*; all paper subsequently published in prestigious scientific journals); (2) Oskar Krantz defended his thesis in 2009 (title: *Social Construction of Technical Aids—Personal Meaning and Interactional Effects of Disability and Assistive Devices in Everyday Life*). His work was performed within the

Vårdal institute; (3) Thomas Eriksson defended his thesis in 2013 (title: *Empirical essays on health and human capital*); (4) Lina-Maria Ellegård defended her thesis in 2013 (title: *Political conflicts over public policy in local governments*); (5) Sofie Lindgren defended her thesis in 2014 (*Essays on Human Capital Investments: Pharmaceuticals and Education*); Laura Pirhonen defended her thesis in 2020 (title: Health-economic evaluation of person-centred care).

SELECTED PUBLICATIONS

Books and book chapters

1. Bolin, K., 1996. An Economic Analysis of Marriage and Divorce. Ph.D. dissertation
2. Bolin, K., 1997. A family with one dominating spouse. In Persson, I., and C. Jonung (eds.). *Economics of the Family and Family Policies*, 84-99. Routledge.
3. Bolin, K., 1998. Alimony. In Newman, P., (ed.). *The New Pelgrave Dictionary of Economics and the Law*, 48-50. Macmillan.
4. Bolin, K., Jacobson, L., and Lindgren, B. The demand for health and health investments in Sweden 1980/81, 1990/91 and 1996/97. In: Lindgren, B. (Ed.) *Individual Decisions for Health*. London: Routledge, 2002: 93 -112.
5. Lundborg, P., Bolin, K., Höjgård, S., Lindgren B. Obesity, wages, and hours worked among the 50+ of Europe. In: Bolin, K; Cawley, J. (Eds) *Advances in Health Economics and Health Services Research 17: The Economics of Obesity*. Elsevier, 2007:219-253.
6. Bolin K, Eklöf M, Höjgård S, Lindgren B. Changes in the health status of the population. In Klevmarken A, Lindgren B (eds) *Simulating An Ageing Population. A Micro-simulation Approach Applied to Sweden*. Contributions to Economic Analysis. Amsterdam: Elsevier, 2008, Chapter 4.
7. Bolin K, Höjgård S, Lindgren B. Sickness absence from work. In Klevmarken A, Lindgren B (eds) *Simulating An Ageing Population. A Micro-simulation Approach Applied to Sweden*. Contributions to Economic Analysis. Amsterdam: Elsevier, 2008, Chapter 5.
8. Bolin K, Matias Eklöf, Daniel Hallberg, Sören Höjgård, Björn Lindgren. Early retirement. In Klevmarken A, Lindgren B (eds) *Simulating An Ageing Population. A Micro-simulation Approach Applied to Sweden*. Contributions to Economic Analysis. Amsterdam: Elsevier, 2008, Chapter 6.
9. Bolin K, Höjgård S, Lindgren B. Utilisation of inpatient care. In Klevmarken A, Lindgren B (eds) *Simulating An Ageing Population. A Micro-simulation Approach Applied to Sweden*. Contributions to Economic Analysis. Amsterdam: Elsevier, 2008, Chapter 10.
10. Bolin K. Health Production. *Oxford Handbook of Health Economics*. Oxford University Press, 2011.

Editor

11. *The Economics of Obesity*. Bolin, K; Cawley, J. (Eds) *Advances in Health Economics and Health Services Research 17: The Economics of Obesity*. Elsevier, 2007.
12. *The Economics of Medical Technology*. Bolin, K; Kaestner, R. (Eds) *Advances in Health Economics and Health Services Research 23: The Economics of Medical Technology*. Elsevier, 2012.
13. *Preference Measurement in Health*. Blomquist, G; Bolin, K. (Eds) *Advances in Health Economics and Health Services Research 24: Preference Measurement in Health*. Elsevier, 2014.
14. *Advances in Health Economics and Health Services Research*. Bolin, K, Grossman, K, Lindgren, B, Sindelar, J, Kaestner R. (Eds). *Human Capital and Health Behaviour*.

Articles in scientific journals

15. Bolin, K., 1994. The marriage contract and efficient rules for spousal support. *International Review of Law and Economics* 14, 493-502.
16. Bolin, K., Jacobson, L., and Lindgren, B. The family as the health producer – when spouses are Nash-bargainers. *Journal of Health Economics* 20; 349-362, 2001.

17. Bolin, K., and Lindgren, B. Asthma and allergy - The significance of chronic conditions for individual health behaviour. *Allergy* 2002;57:115-122.
18. Bolin, K., Jacobson, L., and Lindgren, B. The family as the health producer – when spouses act strategically. *Journal of Health Economics* 2002;21: 475-495.
19. Bolin, K., Jacobson, L., and Lindgren, B. Employer investments in employee health. Implications for the family as health producer. *Journal of Health Economics* 2002;21: 563-583.
20. Bolin, K., Lindgren, B., Lindström, M., and Nystedt, P. Investments in social capital - Implications of social interactions for the production of health. *Social Science and Medicine* 2003;56:2379-90.
21. Lindström, M., Moghaddassi, M., Bolin, K., Lindgren, B., Merlo, J. Social capital and daily tobacco smoking: A population-based multilevel analysis in Malmö, Sweden. *Scandinavian Journal of Public Health*, 2003;31:444-450.
22. Bolin, K., Lindgren, B., and Willers, S. The cost-utility of Bupropion in smoking-cessation health programmes – Simulation model results for Sweden. *Chest* 2006;129:651-660.
23. Bolin, K., Lindgren, B., Rössner, S. The significance of overweight and obesity for individual health behaviour - an economic analysis based on the Swedish surveys of living conditions 1980/81, 1988/89, and 1996/97. *Scandinavian Journal of Public Health*, 2006;34:422-31.
24. Bolin, K., Lindgren, B. Smoking, Healthcare cost, and loss of productivity in Sweden 2001. *Scandinavian Journal of Public Health*, 2007;35:187-196.
25. Bolin, K. Health among long-term survivors of breast cancer - An analysis of 5-year survivors based on the Swedish surveys of living conditions 1979 – 1995 and the Swedish Cancer Registry 2000. *Psycho-Oncology*, 2007;17:1-8.
26. Bolin, K., Lindgren, B., Lundborg, P. Informal and formal care among single-living elderly in Europe. *Health economics*, 2008;17(3):393-409.
27. Bolin, K., Lindgren, B., Lundborg, P. Your next of kin or your own career? Caring and working among the 50+ of Europe. *Journal of Health Economics*, 2008;27:718-738.
28. Krantz, O., Bolin, K., Persson, D. Stigma-handling strategies in everyday life among women aged 20 to 30 with transversal upper limb reduction deficiency. *Scandinavian Journal of Disability Research* 2008;10:209-226.
29. Bolin K, Mörk A-C, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking cessation therapy – cost-utility results for Sweden. *Respiratory Medicine*, 2008;102(5):699-710.
30. Bolin, K, Mörk A-C, Wilson K. Smoking-Cessation Therapy Using Varenicline – The cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. *Journal of Evaluation in Clinical Practice*, 2009;15:478-485.
31. Bolin K, Lindgren A, Lindgren B, Lundborg P. Utilisation of physician services in the 50 + population. The relative importance of individual versus institutional factors in 10 European countries. *International Journal of Health Care Finance and Economics*, 2009;9:83-112.
32. Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork A-C, Aubin H-J. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation— results from 4 European countries. *European Journal of Public Health*, 2009;19:650-654.
33. Bolin K, Gip C, Mörk AC, Lindgren B. Diabetes, healthcare costs and loss of productivity in Sweden 1987 and 2005 – a register-based approach. *Diabetic Medicine*, 2009;26:928-934.
34. Bolin, K, Berggren, F, Forsgren, L. Iacosamide as treatment of epileptic seizures – cost-utility results for Sweden. *Acta Neurologica Scandinavica* 2010;121(6):406-412.

35. Wennick A, Hallström I, Lindgren B, Bolin K. Attained education and self-assessed health later in life when diagnosed with diabetes in childhood: a population-based study. *Pediatric Diabetes* 2011;12(7):619-626.
36. Mathiassen, SE, Bolin, K. Optimizing cost-efficiency in mean exposure assessment – cost functions reconsidered. *BMC Medical Research Methodology*, 2011;11:76.
37. Tingstedt, B, Andersson, E, Flink, A, Bolin, K, Lindgren, B, Andersson, R. Pancreatic cancer, healthcare cost and loss of productivity – a register-based approach. *World Journal of Surgery*, 2011;35:2298–2305.
38. Bolin, K, Borgman, B, Gip, C, Wilson, K. Current and future avoidable cost of smoking – Estimates for Sweden 2007. *Health Policy*, 2011;103:83-91.
39. Bolin, K, Lundgren, A, Berggren, F, Källén, K. Epilepsy in Sweden: healthcare costs and loss of productivity – a register-based approach. *European Journal of Health Economics*, 2012;13(6): 819-826.
40. Bolin, K. Lifestyle, health and costs – what do available evidence suggest? *Nordic Economic Policy Review*. 2012;2:59-97.
41. Bolin, K. Economic value of smoking cessation therapies: a critical and systematic review of simulation-generated evidence. *Pharmacoeconomics*, 2012;30(7):551-564.
42. Bolin, K, Forsgren, L. The cost effectiveness of newer treatments for partial-onset seizures – a review of the literature. *Pharmacoeconomics*, 2012;30(10):903-923.
43. Bolin, K, Wachtmeister, K, Frenning, S, Forsgren, L. The cost-utility of retigabine as add-on treatment of refractory epilepsy. *Acta Neurologica Scandinavica*, 2013;127(6):419-426.
44. Bolin, K, Sandin, R, Koltowska-Häggström, M, Loftus, J, Prütz, C, Jonsson, B. The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden. *Cost Effectiveness and Resource Allocation*, 2013;24:1-13.
45. Bolin, K, Berggren, F, Landtblom, AM. Regional variation in the prevalence, healthcare utilization and cost of epilepsy in Sweden. *Acta Neurologica Scandinavica*, 2014;130:354-359.
46. Bolin, K, Berggren, F, Landtblom, AM. Prevalence and cost of epilepsy in Sweden – a register-based approach. *Acta Neurologica Scandinavica*, 2015;131: 37–44.
47. Green, A, Ramey, DR, Emneus, M, Iachina, M, Stavem, K, Bolin, K, McNally, R, Busch-Sørensen, M, Willenheimer, R, Egstrup, K, Kesäniemi, A, Ray, S, Basta, N, Kent, C, Pedersen, TR. Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial. *American Journal of Cardiology*, 2014;114:1518–1522.
48. Kjørulff, TM, Ersbøll, AK, Green, A, Emneus, M, Pukkala, E, Bolin, K, Stavem, K, Iversen, P, Brasso, K, Hallas, J, and Thygesen, LC. Patterns of finasteride use in the male populations of four Nordic countries: a cross-national drug utilisation study. *Scandinavian Journal of Urology*, 2016;50:220-227.
49. Elden, H, Hagberg, H, Wessberg, A, Sengpiel, V, Herbst, A, Bullarbo, M, Bergh, C, Bolin, K, Malbasic, S, Saltvedt, S, Stephansson, O, Wikström, AK, Ladfors, L, Wennerholm, UB. Study protocol of SWEPIS a Swedish multicentre register based randomized controlled trial to compare induction of labour at 41 completed gestational weeks versus expectant management and induction at 42 completed gestational weeks. *BMC Pregnancy and Childbirth* (2016) 16:49.
50. Bolin, K, Lindgren, B. Non-monotonic health behaviours – implications for individual health-related behaviour in a demand-for-health framework. *Journal of Health Economics*, 2016;50:9-26.
51. Pirhonen, L, Olofsson, EH, Fors, A, Ekman, I, Bolin, K. Effects of person-centred care on health outcomes - A randomized controlled trial in patients with acute coronary syndrome. Forthcoming in *Health Policy*, 2017;121(2):169-179

52. Bolin, K, Berggren, F, Berling, P, Morberg, S, Gauffin, H, Landtblom, AM. Patterns of antiepileptic drug prescription in Sweden: a register-based approach. *Acta Neurologica Scandinavica*, 2017;136(5):521-527.
53. Bolin, K, Berling, P, Wasling, P, Meinild, H, Kjellberg, J, Jennum, P. The cost-utility of sodium oxybate as narcolepsy treatment. *Acta Neurologica Scandinavica*, 2017;136(6):715-720.
54. Meijer M, Thygesen LC, Green A, Emneus M, Brasso K, Iversen P, Pukkala E, Bolin K, Stavem K, Kjær Ersbøll A. Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries. *Cancer Medicine*, 2018;7(1):254-260.
55. McEwan P, Bennett H, Bolin K, Evans M, Bergenheim K. Assessing the economic value of maintained improvements in type 1 diabetes management, in terms of HbA1c, weight and hypoglycaemic event incidence. *Diabetic Medicine*, 2018;35(5):557-566.
56. Bolin K. Physical inactivity – productivity losses and healthcare costs 2002 and 2016 in Sweden. *BMJ Open Sport & Exercise Medicine*, 2018;4:e000451. doi: 10.1136/bmjsem-2018-000451.
57. Barbieri P, Bolin, K. Digitalizing and collecting health data in Sweden. *Pharmaceuticals Policy and Law*, 2018;19:235-245.
58. Majlund Kjærulff T, Kjær Ersbøll A, Pukkala E, Bolin K, Green A, Emneus M, Brasso K, Iversen P, Caspar Thygesen L. Finasteride use and risk of male breast cancer: a case-control study using individual-level registry data from Denmark, Finland, and Sweden. *Cancer Epidemiology, Biomarkers & Prevention*, 2019;28(5):980-986.
59. Pirhonen L, Bolin K, Hansson Olofsson E, Fors F, Ekman I, Swedberg K, Gyllenstein H. Person-centred care in patients with acute coronary syndrome: cost-effectiveness analysis alongside a randomised controlled trial. *Pharmacoeconomics*, 2019, <https://doi.org/10.1007/s41669-019-0126-3>.
60. Bolin K, Hertervig E, Louis E. The cost-effectiveness of biological therapy cycles in the management of Crohn's disease. *Journal of Crohn's and Colitis*, 2019;27;13(10):1323-1333.
61. Sengupta K, Thygesen LC, Søbø Kristiansen I, Bolin K, Pukkala E, Emneus M, Bøge Christensen L, Kjær Ersbøll A. Utilization of etoricoxib in dental patients in the Nordic countries: a population-based register study. *Acta Odontologica Scandinavica*, 2019;77(8):584-591.
62. König S, E. Johansson B, Bolin K. Invisible scars or open wounds? The role of mid-career income for the gender pension gap in Sweden. *Frontiers in Sociology*, 2019.
63. Majlund Kjærulff T, Kjær Ersbøll A, Pukkala E, Bolin K, Green A, Emneus M, Brasso K, Iversen P, Caspar Thygesen L. Characteristics of finasteride users in comparison with non-users: a Nordic nationwide study based on individual-level data from Denmark, Finland, and Sweden. *Pharmacoepidemiology and Drug Safety*, 2020.
64. Bolin K. The cost-utility of pitolisant as narcolepsy treatment, *Acta Neurologica Scandinavica*, 2020;141:301-310.
65. Castor C, Bolin K, Hansson H, Landgren K, Kristensson Hallström I. Healthcare costs and productivity losses associated with county-based home-care service for sick children in Sweden. *Scandinavian Journal of Caring Sciences*, 2020.
66. Andersson K, Ozanne A, Edelvik A, Chaplin J, Bolin K, Malmgren K, Zelano J. Socioeconomic outcome and access to care in adults with epilepsy in Sweden: a nationwide cohort study. *Seizure*, 2020;74:71-76.
67. Bolin K, Caputo MR. Consumption and Investment Demand when Health Evolves Stochastically. *Journal of Economic Dynamics and Control*, 2020;114:.
68. Pirhonen L, Bolin K. The cost-effectiveness of person-centred care provided to patients with chronic heart failure and/or chronic obstructive pulmonary disease. *Health Policy*.

69. Pirhonen L, Fors A, Gyllensten H, Bolin K. Modelling the cost-effectiveness of person-centred care for patients with acute coronary syndrome. *European Journal of Health Economics*, forthcoming.
70. Andersson K, Ozanne A, Bolin K, Tomson T, Zelano J. Valproic acid and socioeconomic associations in Swedish women with epilepsy 2010-2015. Forthcoming *Acta Neurologica Scandinavica*